When Katie Tinkler was 20, a diagnosis of lupus forced her to give up her career as a fitness instructor. For three decades, the disease—causing swollen joints, kidney damage, lung and heart problems, and dangerous blood clots—ruled her life. At its worst, she experienced sepsis and multi-organ failure, spending time in an induced coma in intensive care. She couldn't lift a mug with her hands. Her kidneys, heart and lungs were failing. Now 52, Tinkler from Guildford, Surrey, has skied for the first time in a decade and danced at her daughter's wedding. "My whole system was affected by lupus and my joints were so painful that sometimes I couldn't walk," she said. "But now I don't have these problems any more. It's miraculous for me. My life two years ago versus now, it's unrecognisable. I feel blessed."
Tinkler is one of five patients now in remission after a pioneering NHS trial of CAR-T cell therapy at University College London Hospitals (UCLH). The treatment works by extracting a patient's own T lymphocytes—white blood cells crucial for hunting damaged cells—and engineering them to recognize and destroy disease. The modified cells are then infused back into the patient, effectively resetting the immune system. Nine patients with severe lupus, none of whom had responded to previous treatments, were recruited for the trial led by UCLH and University College London. Most had lupus nephritis, a serious complication affecting the kidneys.
Six patients received a lower dose of the therapy, while three received a higher dose. Of those on the lower dose, who were followed for an average of 11 months, all five achieved remission within just a few months. The three patients on the higher dose have only been followed for three months so far, but doctors are cautiously optimistic they too will reach remission. Tests showed rapid improvements in disease markers, including stabilization or recovery of kidney function that had been damaged by lupus.
Lupus is a chronic autoimmune condition where the immune system mistakenly attacks healthy tissue, causing widespread inflammation and organ damage. The disease affects approximately 5 million people worldwide and predominantly impacts women. It can range from mild to severe, with symptoms including joint pain, skin problems, and fatigue. What makes CAR-T therapy so groundbreaking is that patients require only a single treatment course—potentially eliminating the need for lifelong medication.
Professor Karl Peggs, director of UCLH's biomedical research centre, said the findings represent a genuine turning point. "These findings are truly groundbreaking and offer fresh hope to people living with lupus," he said. "While more research is needed, the possibility that CAR T-cell therapy could deliver an immune reset and potentially free patients from the cycle of chronic autoimmune disease marks a remarkable step forward. If these results are confirmed in larger studies, the prospect of a cure for lupus may no longer be out of reach."
For Tinkler, the transformation is already tangible. "Thinking about how life was for beforehand and how it is now, it's like night and day," she said. "I couldn't use my hands to pick up mugs. My kidneys, heart and lungs were all getting worse." Now, with her three adult children and husband by her side, she is simply grateful for what she calls an unmerited gift. The therapy, already revolutionizing cancer treatment, may be on the cusp of doing the same for autoimmune disease.